Logo ofLeen Alkhair Trading Co. 
Leen Alkhair Trading Co. stated that its accumulated losses reached SAR 25.61 million, representing 31% of the company’s SAR 81.6 million share capital, according to H1 2026 financial statements.
According to a statement on Tadawul, the losses were mainly attributable to the group’s results swinging from a net profit of SAR 2.28 million in H1 2025 to a net loss of SAR 17.98 million in H1 2026.
This was primarily due to a 15.3% decline in sales, which resulted in gross profit of SAR 12.49 million turning into a gross loss of SAR 6.95 million. This came as the cost of sales declined by only around 0.9%, compared with the 15.3% drop in sales, resulting in a significant deterioration in the gross profit margin.
Results were also affected by higher operating costs, including wages, depreciation and transportation, as well as the recognition of a SAR 3.06 million impairment provision for biological assets.
General and administrative expenses rose to SAR 6.28 million from SAR 4.78 million, while an expected credit loss provision of SAR 1.70 million was recognized, compared with SAR 0.39 million in the same period last year. Financing costs also increased to SAR 1.48 million from SAR 1.29 million.
Meanwhile, selling and distribution expenses declined to SAR 2.01 million from SAR 3.42 million.
The company added that the procedures and regulations applicable to listed companies whose accumulated losses reach 20% or more of their share capital will be implemented.
Logo ofLeen Alkhair Trading Co.
Leen Alkhair Trading Co. stated that its accumulated losses reached SAR 25.61 million, representing 31% of the company’s SAR 81.6 million share capital, according to H1 2026 financial statements.
According to a statement on Tadawul, the losses were mainly attributable to the group’s results swinging from a net profit of SAR 2.28 million in H1 2025 to a net loss of SAR 17.98 million in H1 2026.
This was primarily due to a 15.3% decline in sales, which resulted in gross profit of SAR 12.49 million turning into a gross loss of SAR 6.95 million. This came as the cost of sales declined by only around 0.9%, compared with the 15.3% drop in sales, resulting in a significant deterioration in the gross profit margin.
Results were also affected by higher operating costs, including wages, depreciation and transportation, as well as the recognition of a SAR 3.06 million impairment provision for biological assets.
General and administrative expenses rose to SAR 6.28 million from SAR 4.78 million, while an expected credit loss provision of SAR 1.70 million was recognized, compared with SAR 0.39 million in the same period last year. Financing costs also increased to SAR 1.48 million from SAR 1.29 million.
Meanwhile, selling and distribution expenses declined to SAR 2.01 million from SAR 3.42 million.
The company added that the procedures and regulations applicable to listed companies whose accumulated losses reach 20% or more of their share capital will be implemented.
